Central Nervous System News and Research

RSS

ImmunoCellular Therapeutics receives U.S. patent for cancer vaccine technology

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a U.S. patent relating to a technology for the treatment of cancer for which the Company holds an exclusive, worldwide license.

22 Jun 2011

Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

Pfizer Inc. announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica compared to placebo.

22 Jun 2011

Scientists discover molecular mechanism that could help develop new MS treatments

Scientists at The University of Nottingham have discovered a molecular mechanism which could bring about the development of new treatments for Multiple Sclerosis (MS) — a chronic inflammatory disease of the central nervous system.

22 Jun 2011

NextGen launches first CSF multiplex protein assay for detecting CNS diseases

NextGen Group plc is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first cerebrospinal fluid (CSF) multiple protein assay, csfdiscovery43, for central nervous system (CNS) biomarker discovery and qualification.

21 Jun 2011

Neuroscientists to discuss future of mental health treatments at NCDEU meeting

More than 1,000 of the world's leading neuroscientists gathered this week at the 51st Annual NCDEU Meeting to discuss the future of mental health treatments.

21 Jun 2011

Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity

Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform. CTP-499 is progressing into Phase 2 clinical trials for diabetic nephropathy and C-21191 has been selected as a lead candidate for spasticity.

20 Jun 2011

Study provides insight into how humans and other vertebrates generate sounds

Cornell researchers have identified regions of a fish brain that reveal the basic circuitry for how humans and other vertebrates generate sound used for social communication.

16 Jun 2011

Stem cell technology corrects genetic defect in rare blinding disorder

Researchers have used cutting-edge stem cell technology to correct a genetic defect present in a rare blinding disorder, another step on a promising path that may one day lead to therapies to reverse blindness caused by common retinal diseases such as macular degeneration and retinitis pigmentosa which affect millions of individuals.

16 Jun 2011

Scientists discover Sonic Hedgehog protein's mechanism of action

A scientific breakthrough by researchers at the Institut de recherches cliniques de Montréal (IRCM) will be published tomorrow in Developmental Cell, a scientific journal of the Cell Press group. Led by Dr. Frédéric Charron, the team of scientists discovered a new requirement for the proper functioning of the Sonic Hedgehog protein.

14 Jun 2011

Scientists find novel form of brain plasticity

Scientists have known for years that neurogenesis takes place throughout adulthood in the hippocampus of the mammalian brain. Now Columbia researchers have found that under stressful conditions, neural stem cells in the adult hippocampus can produce not only neurons, but also new stem cells.

14 Jun 2011

Risky behavior, psychiatric disorders and substance abuse contribute to opioid overdose

Deaths related to prescription opioid therapy are under intense scrutiny, prompting those in pain medicine-clinicians, patient advocates, and regulators-to understand the causes behind avoidable mortality in legitimately treated patients.

13 Jun 2011

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

Data to be presented tomorrow at the 16th Annual Meeting of the European Hematology Association (EHA) in London, UK, show that Micromet's blinatumomab produced a high complete remission rate in adult patients with acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy.

10 Jun 2011

Platelet-derived growth factor-BB restores function in rats with Parkinson's disease

Few treatments for Parkinson's disease (PD) restore function for extended periods. In a new study published today in the inaugural issue of the Journal of Parkinson's Disease, an international group of researchers report that platelet-derived growth factor-BB (PDGF-BB) restored function in rodents and shows promise as a clinical candidate drug for treatment of PD.

10 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

Key molecule of vascular system directs axons during neural circuit formation

Dr. Fr-d-ric Charron, researcher at the Institut de recherches cliniques de Montr-al (IRCM), and his team have shown for the first time that a key molecule of the vascular system directs axons during the formation of neural circuits.

9 Jun 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

New insights into understanding of neurological disorders

Increasingly sophisticated imaging tools and techniques are emerging that make it possible to probe the organization and activity of the brain at the cellular and molecular level, leading to a better understanding of the complex networks that link brain structure and function.

8 Jun 2011

Survivors of childhood cancer at increased risk of developing subsequent primary neoplasms

In a study that included nearly 18,000 children who had cancer, with follow-up of about 25 years, the greatest excess risk associated with a subsequent primary neoplasm (a new tumor) at older than age 40 years was for digestive and genitourinary neoplasms (related to the genital or urinary tract organs), according to a study in the June 8 issue of JAMA, a theme issue on cancer.

7 Jun 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

Anti-ghrelin vaccine decreases food intake and increases calorie burning in mice

A new therapeutic vaccine to treat obesity by suppressing the appetite-stimulating hormone ghrelin decreases food intake and increases calorie burning in mice, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Central Nervous System News and Research

ImmunoCellular Therapeutics receives U.S. patent for cancer vaccine technology

Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

Scientists discover molecular mechanism that could help develop new MS treatments

NextGen launches first CSF multiplex protein assay for detecting CNS diseases

Neuroscientists to discuss future of mental health treatments at NCDEU meeting

Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity

Study provides insight into how humans and other vertebrates generate sounds

Stem cell technology corrects genetic defect in rare blinding disorder

Scientists discover Sonic Hedgehog protein's mechanism of action

Scientists find novel form of brain plasticity

Risky behavior, psychiatric disorders and substance abuse contribute to opioid overdose

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

Platelet-derived growth factor-BB restores function in rats with Parkinson's disease

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Key molecule of vascular system directs axons during neural circuit formation

NYU Cancer Institute scientists present new research findings at ASCO 2011

New insights into understanding of neurological disorders

Survivors of childhood cancer at increased risk of developing subsequent primary neoplasms

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Anti-ghrelin vaccine decreases food intake and increases calorie burning in mice

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News